Loading clinical trials...

Na-Phenylbutyrate VAscular Trial | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGEARLY_PHASE1

Na-Phenylbutyrate VAscular Trial

NCT06645769•University of Pennsylvania

Summary

This study will investigate if the drug sodium phenylbutyrate (NaPB) impacts blood pressure and vascular function in healthy volunteers and in patients with diabetes.

Eligibility

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Over 18 years of age and less than 60.
•Healthy subjects will have no history of diabetes or prediabetes.
•Diabetes subjects can be either insulin dependent or not.
•Able to provide written consent and to comply with the procedures of the study protocol.

Exclusion Criteria

•Age \<18 or \>60
•Pregnant or lactating women.
•Subjects with hypertension or taking any vasodilatory medications, any steroidal drugs, haloperidol, or valproic acid.
•Patients with congestive heart failure, severe renal insufficiency, hepatic failure, or known sodium retention with oedema.
•Active alcohol or substance abuse.
•Use of tobacco within the previous six months.
•Unble to provide written consent and to comply with the procedures of the study protocol.

Key Dates

Start Date

June 1, 2026

Primary Completion Date

January 1, 2028

Completion Date

June 1, 2029

Last Updated

March 12, 2026

Enrollment

ESTIMATED participants

Conditions

Diabetes

Interventions

Sodium Phenylbutyrate

DRUG

Placebo

OTHER

Contacts

Claire Brady

CONTACT

8573344274 Claire.Brady@Pennmedicine.upenn.edu

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITING

Genetic Studies of Insulin and Diabetes

NCT00001987

Diabetes MellitusSevere Insulin Resistance

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 12, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Na-Phenylbutyrate VAscular Trial

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Genetic Studies of Insulin and Diabetes

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

Mesenchymal Stem Cell and Exosome Therapy for Diabetic Erectile Dysfunction

Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes